作者: S. R. Riddell , E. H. Warren , D. Lewinsohn , H. Mutimer , M. Topp
DOI: 10.1007/978-3-662-04183-3_4
关键词:
摘要: Improvements in our understanding of the molecular basis for T cell recognition virus-infected cells and tumors, signals involved eliciting maintaining a competent immune response has led to new efforts bolster host immunity settings where deficient responses permit disease progression. The identification viral antigens expressed by tumors develop adoptive immunotherapy with clones as therapeutic approach restore or augment (Riddell Greenberg 1995). early results clinical studies therapy diseases have been encouraging this is now being developed treatment patients leukemia that recurs after allogeneic bone marrow transplant (BMT) solid tumors.